Disclosures for "The First Light: Efficacy and Safety of a Multi-dose Study of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One"
-
The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TAKEDA. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOPROJET. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA/CENTESSA.
-
Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals, Inc. . Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for EcoR1. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for ApneaCo. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Centessa .
-
Dr. Arnulf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO Pharma. Dr. Arnulf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE pharma. Dr. Arnulf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IDORSIA Pharma. Dr. Arnulf has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for UCB Pharma. The institution of Dr. Arnulf has received research support from BIOPROJET pharma. The institution of Dr. Arnulf has received research support from VITALAIRE. The institution of Dr. Arnulf has received research support from French SLEEP Socity (SFRMS). The institution of Dr. Arnulf has received research support from Paris Brain Insitute. Dr. Arnulf has a non-compensated relationship as a scientific advisory with Jazz Pharma that is relevant to AAN interests or activities. Dr. Arnulf has a non-compensated relationship as a scientific advisory with Theranexus that is relevant to AAN interests or activities.
-
Dr. Del Río Villegas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TAKEDA. Dr. Del Río Villegas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ALKERMES.
-
Dr. Khatami has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Pharmaceuticals International AG. Dr. Khatami has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Khatami has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. Dr. Khatami has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda Pharmaceuticals International AG. Dr. Khatami has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Idorsia. Dr. Khatami has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda Pharmaceuticals International AG. Dr. Khatami has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Swiss Insurance Medicine.
-
The institution of Dr. Lammers has received research support from Takeda.
-
Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda Pharmaceutical Company Limited. Dr. Taniguchi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai Co., Ltd.. Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai Co., Ltd.. Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai Co., Ltd.. An immediate family member of Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teijin Pharma Limited. Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teijin Pharma Limited. Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teijin Pharma Limited. Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alfresa Pharma Corporation. Dr. Taniguchi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alfresa Pharma Corporation.
-
Dr. Kadali has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Dr. Kadali has stock in Takeda Pharmaceuticals.
-
Yeting Du has received personal compensation for serving as an employee of Takeda Pharmaceuticals.
-
Dr. Hsiao has received personal compensation for serving as an employee of Takeda. Dr. Hsiao has stock in Takeda.
-
Dr. Olsson has received personal compensation for serving as an employee of Takeda. Dr. Olsson has stock in Takeda.
-
Dr. Sheikh has received personal compensation for serving as an employee of Takeda.
-
Author has nothing to disclose
-
Dr. Etherton has received personal compensation for serving as an employee of Takeda Pharmaceutical Company. Dr. Etherton has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Argenica Therapeutics.
-
Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alkermes. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Centessa. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bioprojet. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony Bioscience.